Interest of a third dose of BNT162b2 anti‐SARS‐CoV‐2 messenger RNA vaccine after allotransplant
Open Access
- 20 October 2021
- journal article
- letter
- Published by Wiley in British Journal of Haematology
- Vol. 196 (5), E38-E40
- https://doi.org/10.1111/bjh.17911
Abstract
No abstract availableThis publication has 10 references indexed in Scilit:
- Randomized Trial of a Third Dose of mRNA-1273 Vaccine in Transplant RecipientsThe New England Journal of Medicine, 2021
- Antibody response after third BNT162b2 dose in recipients of allogeneic HSCTThe Lancet Haematology, 2021
- Safety and Antibody Response After 1 and 2 Doses of BNT162b2 mRNA Vaccine in Recipients of Allogeneic Hematopoietic Stem Cell TransplantJAMA Network Open, 2021
- Three Doses of an mRNA Covid-19 Vaccine in Solid-Organ Transplant RecipientsThe New England Journal of Medicine, 2021
- Efficiency of a boost with a third dose of anti-SARS-CoV-2 messenger RNA-based vaccines in solid organ transplant recipientsAmerican Journal of Transplantation, 2021
- Antibody response after second BNT162b2 dose in allogeneic HSCT recipientsThe Lancet, 2021
- A correlate of protection for SARS-CoV-2 vaccines is urgently neededNature Medicine, 2021
- Reduced sensitivity of SARS-CoV-2 variant Delta to antibody neutralizationNature, 2021
- Safety and Immunogenicity of the BNT162b2 mRNA COVID-19 Vaccine in Patients after Allogeneic HCT or CD19-based CART therapy—A Single-Center Prospective Cohort StudyTransplantation and Cellular Therapy, 2021
- Safety and Immunogenicity of Two RNA-Based Covid-19 Vaccine CandidatesThe New England Journal of Medicine, 2020